[{"id":"9b2dd962-db93-43b8-b077-57bd460b2d26","acronym":"","url":"https://clinicaltrials.gov/study/NCT04996823","created_at":"2021-08-09T13:53:12.104Z","updated_at":"2025-02-25T15:19:13.745Z","phase":"Phase 2","brief_title":"Axitinib + Ipilimumab in Advanced Melanoma","source_id_and_acronym":"NCT04996823","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • axitinib"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 08/04/2021","start_date":" 08/04/2021","primary_txt":" Primary completion: 03/29/2026","primary_completion_date":" 03/29/2026","study_txt":" Completion: 03/29/2027","study_completion_date":" 03/29/2027","last_update_posted":"2025-02-12"},{"id":"56bb338a-9a55-47ed-87d8-9a54d97136da","acronym":"","url":"https://clinicaltrials.gov/study/NCT03595124","created_at":"2021-01-18T17:40:40.562Z","updated_at":"2025-02-25T16:31:25.872Z","phase":"Phase 2","brief_title":"A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)","source_id_and_acronym":"NCT03595124","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • PD-1 • CD38 • PTPRC • CD69 • TFE3 • CD14 • CD24 • ITGAM • FOXP3","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • CD38 • PTPRC • CD69 • TFE3 • CD14 • CD24 • ITGAM • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • axitinib • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/08/2019","start_date":" 01/08/2019","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 01/23/2026","study_completion_date":" 01/23/2026","last_update_posted":"2025-02-07"},{"id":"d8a6d977-6f13-416a-b8b4-9b7236d1ef6b","acronym":"TAPUR","url":"https://clinicaltrials.gov/study/NCT02693535","created_at":"2021-01-17T17:24:20.327Z","updated_at":"2025-02-25T14:00:57.498Z","phase":"Phase 2","brief_title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","source_id_and_acronym":"NCT02693535 - TAPUR","lead_sponsor":"American Society of Clinical Oncology","biomarkers":" BRAF","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • sunitinib • tamoxifen • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Bavencio (avelumab) • Talzenna (talazoparib) • Verzenio (abemaciclib) • albumin-bound paclitaxel • cyclophosphamide • Stivarga (regorafenib) • fulvestrant • Lytgobi (futibatinib) • Tukysa (tucatinib) • temsirolimus • letrozole • axitinib • epirubicin • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 3791","initiation":"Initiation: 03/14/2016","start_date":" 03/14/2016","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-01-29"},{"id":"613dfa54-e318-471f-a8ed-a12b2572968b","acronym":"CAPTUR","url":"https://clinicaltrials.gov/study/NCT03297606","created_at":"2021-01-18T16:17:30.914Z","updated_at":"2025-02-25T13:52:23.697Z","phase":"Phase 2","brief_title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","source_id_and_acronym":"NCT03297606 - CAPTUR","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Zelboraf (vemurafenib) • sunitinib • Perjeta (pertuzumab) • Cotellic (cobimetinib) • bosutinib • Tukysa (tucatinib) • temsirolimus • axitinib • Erivedge (vismodegib)"],"overall_status":"Recruiting","enrollment":" Enrollment 720","initiation":"Initiation: 03/23/2018","start_date":" 03/23/2018","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2024-11-12"},{"id":"62fde8ea-b4f1-4e11-9442-c58db1f54a1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04688658","created_at":"2021-01-19T20:48:11.081Z","updated_at":"2025-02-25T14:29:48.942Z","phase":"Phase 1/2","brief_title":"Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma","source_id_and_acronym":"NCT04688658","lead_sponsor":"John Kirkwood","biomarkers":" BRAF • CD8","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • axitinib • Copiktra (duvelisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 07/21/2021","start_date":" 07/21/2021","primary_txt":" Primary completion: 02/22/2024","primary_completion_date":" 02/22/2024","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-08-08"},{"id":"ef2ab7b8-a2e5-4df2-83fe-3e4e96f58f67","acronym":"","url":"https://clinicaltrials.gov/study/NCT04693468","created_at":"2021-01-19T20:49:06.628Z","updated_at":"2024-07-02T16:34:58.952Z","phase":"Phase 1","brief_title":"Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial","source_id_and_acronym":"NCT04693468","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ALK • MET • BRCA1 • BRCA2 • ROS1 • RAD51C • RAD51D","pipe":" | ","alterations":" MET amplification • MET mutation • MET expression • ALK translocation","tags":["ALK • MET • BRCA1 • BRCA2 • ROS1 • RAD51C • RAD51D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET mutation • MET expression • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Ibrance (palbociclib) • Talzenna (talazoparib) • axitinib"],"overall_status":"Recruiting","enrollment":" Enrollment 111","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 09/03/2025","primary_completion_date":" 09/03/2025","study_txt":" Completion: 09/03/2025","study_completion_date":" 09/03/2025","last_update_posted":"2024-06-04"},{"id":"080b8b58-50bf-4327-9274-58c6a55f5dce","acronym":"","url":"https://clinicaltrials.gov/study/NCT04493203","created_at":"2021-01-18T21:35:04.129Z","updated_at":"2025-02-25T14:29:28.960Z","phase":"Phase 2","brief_title":"Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma","source_id_and_acronym":"NCT04493203","lead_sponsor":"Yana Najjar","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • axitinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 12/18/2020","start_date":" 12/18/2020","primary_txt":" Primary completion: 04/15/2024","primary_completion_date":" 04/15/2024","study_txt":" Completion: 02/28/2029","study_completion_date":" 02/28/2029","last_update_posted":"2024-05-07"},{"id":"6843c310-89f3-4a46-822e-007bc52f641b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05420220","created_at":"2022-06-15T15:55:24.895Z","updated_at":"2024-07-02T16:35:06.663Z","phase":"Phase 2","brief_title":"Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05420220","lead_sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" ALK translocation • EGFR negative","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK translocation • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e axitinib • erfonrilimab (KN046)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 07/15/2022","start_date":" 07/15/2022","primary_txt":" Primary completion: 05/29/2027","primary_completion_date":" 05/29/2027","study_txt":" Completion: 12/26/2027","study_completion_date":" 12/26/2027","last_update_posted":"2024-05-01"},{"id":"c67606ea-7796-46a1-9d35-f3d0edacc3ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT02912572","created_at":"2021-01-18T14:17:54.432Z","updated_at":"2024-07-02T16:35:08.730Z","phase":"Phase 2","brief_title":"Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer","source_id_and_acronym":"NCT02912572","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" MSI • POLE • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR • POLE mutation • MSH6 expression","tags":["MSI • POLE • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • POLE mutation • MSH6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • Talzenna (talazoparib) • axitinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 11/14/2016","start_date":" 11/14/2016","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-04-19"},{"id":"d4b3afea-d3d9-4419-8a44-fcb045a46c84","acronym":"LANDSCAPE 1011","url":"https://clinicaltrials.gov/study/NCT04585815","created_at":"2021-01-18T21:52:42.284Z","updated_at":"2024-07-02T16:35:11.290Z","phase":"Phase 1/2","brief_title":"Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)","source_id_and_acronym":"NCT04585815 - LANDSCAPE 1011","lead_sponsor":"Pfizer","biomarkers":" PD-L1","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib) • axitinib • Zumrad (sasanlimab) • SEA-TGT"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 11/10/2020","start_date":" 11/10/2020","primary_txt":" Primary completion: 05/17/2023","primary_completion_date":" 05/17/2023","study_txt":" Completion: 06/17/2024","study_completion_date":" 06/17/2024","last_update_posted":"2024-04-05"},{"id":"8abb3331-04ba-4bfa-a734-5fadb9a6b09e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04458259","created_at":"2021-08-31T17:53:09.115Z","updated_at":"2024-07-02T16:35:11.509Z","phase":"Phase 1","brief_title":"Study of PF-07265807 in Participants With Metastatic Solid Tumors.","source_id_and_acronym":"NCT04458259","lead_sponsor":"Pfizer","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e axitinib • Zumrad (sasanlimab) • PF-07265807"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 09/24/2020","start_date":" 09/24/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-04-03"},{"id":"a435469f-1cf1-4b7f-a476-32a5089846f8","acronym":"PIVOT IO 011","url":"https://clinicaltrials.gov/study/NCT04540705","created_at":"2021-01-18T21:43:33.570Z","updated_at":"2024-07-02T16:35:17.512Z","phase":"Phase 1","brief_title":"A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread","source_id_and_acronym":"NCT04540705 - PIVOT IO 011","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • axitinib • bempegaldesleukin (NKTR-214)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 09/11/2020","start_date":" 09/11/2020","primary_txt":" Primary completion: 01/18/2024","primary_completion_date":" 01/18/2024","study_txt":" Completion: 01/18/2024","study_completion_date":" 01/18/2024","last_update_posted":"2024-02-28"},{"id":"4940e693-9465-46a4-adde-f09648b1d496","acronym":"JAVELIN Renal 101","url":"https://clinicaltrials.gov/study/NCT02684006","created_at":"2021-01-17T17:21:28.108Z","updated_at":"2024-07-02T16:35:25.303Z","phase":"Phase 3","brief_title":"A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)","source_id_and_acronym":"NCT02684006 - JAVELIN Renal 101","lead_sponsor":"Pfizer","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • Bavencio (avelumab) • axitinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 888","initiation":"Initiation: 03/23/2016","start_date":" 03/23/2016","primary_txt":" Primary completion: 08/31/2023","primary_completion_date":" 08/31/2023","study_txt":" Completion: 05/21/2024","study_completion_date":" 05/21/2024","last_update_posted":"2023-12-22"},{"id":"25c7b019-743d-46cc-aac4-5069f47680db","acronym":"","url":"https://clinicaltrials.gov/study/NCT04337970","created_at":"2021-01-18T20:59:58.456Z","updated_at":"2024-07-02T16:35:26.265Z","phase":"Phase 1/2","brief_title":"Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer","source_id_and_acronym":"NCT04337970","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PD-L1 • PD-1","pipe":"","alterations":" ","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • axitinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 04/06/2020","start_date":" 04/06/2020","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-12-14"},{"id":"ccd9d2d9-556d-4fea-a3cc-f4af558628f0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05012865","created_at":"2021-08-19T14:52:52.672Z","updated_at":"2024-07-02T16:35:26.910Z","phase":"","brief_title":"Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART)","source_id_and_acronym":"NCT05012865","lead_sponsor":"Pfizer","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • axitinib"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 01/31/2022","primary_completion_date":" 01/31/2022","study_txt":" Completion: 01/31/2022","study_completion_date":" 01/31/2022","last_update_posted":"2023-12-06"},{"id":"f8beb39f-22d1-4bc0-8c73-5790f2f0aa80","acronym":"","url":"https://clinicaltrials.gov/study/NCT05808608","created_at":"2023-04-11T14:03:45.332Z","updated_at":"2024-07-02T16:35:35.848Z","phase":"Phase 1/2","brief_title":"A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma","source_id_and_acronym":"NCT05808608","lead_sponsor":"Hao Zeng","biomarkers":" TFE3","pipe":"","alterations":" ","tags":["TFE3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e axitinib • Kaitanni (cadonilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-09-25"},{"id":"8f8790f1-33c5-4117-9b29-b1d397868ea7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03092856","created_at":"2021-01-18T15:14:12.812Z","updated_at":"2024-07-02T16:35:40.288Z","phase":"Phase 2","brief_title":"Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer","source_id_and_acronym":"NCT03092856","lead_sponsor":"University of Southern California","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e axitinib • ivuxolimab (PF-04518600)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 07/19/2017","start_date":" 07/19/2017","primary_txt":" Primary completion: 07/19/2024","primary_completion_date":" 07/19/2024","study_txt":" Completion: 07/19/2025","study_completion_date":" 07/19/2025","last_update_posted":"2023-08-11"},{"id":"5d80783d-8024-40cb-baf3-eb9702119571","acronym":"","url":"https://clinicaltrials.gov/study/NCT05904730","created_at":"2023-06-15T17:08:26.804Z","updated_at":"2024-07-02T16:35:43.282Z","phase":"Phase 1","brief_title":"Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations","source_id_and_acronym":"NCT05904730","lead_sponsor":"Lynkcell Europe","biomarkers":" HER-2 • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HER-2 mutation • HER-2 expression • BRCA mutation","tags":["HER-2 • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HER-2 mutation • HER-2 expression • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e axitinib"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 30","initiation":"Initiation: 07/11/2023","start_date":" 07/11/2023","primary_txt":" Primary completion: 09/24/2024","primary_completion_date":" 09/24/2024","study_txt":" Completion: 11/09/2024","study_completion_date":" 11/09/2024","last_update_posted":"2023-07-12"},{"id":"5197a8d8-b8f2-40ff-b204-a6bf678e416c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02579811","created_at":"2021-01-18T12:30:36.043Z","updated_at":"2024-07-02T16:35:44.347Z","phase":"Phase 2","brief_title":"Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer","source_id_and_acronym":"NCT02579811","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" PD-1","pipe":"","alterations":" ","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e axitinib"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 12/30/2015","start_date":" 12/30/2015","primary_txt":" Primary completion: 08/21/2019","primary_completion_date":" 08/21/2019","study_txt":" Completion: 06/20/2023","study_completion_date":" 06/20/2023","last_update_posted":"2023-06-29"},{"id":"0fffa25c-9476-4ea6-80d2-44bdcf226e67","acronym":"","url":"https://clinicaltrials.gov/study/NCT05738694","created_at":"2023-02-22T15:01:01.286Z","updated_at":"2024-07-02T16:35:48.603Z","phase":"Phase 2","brief_title":"Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma","source_id_and_acronym":"NCT05738694","lead_sponsor":"ZHOU FANGJIAN","biomarkers":" PD-1","pipe":"","alterations":" ","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • axitinib"],"overall_status":"Recruiting","enrollment":" Enrollment 246","initiation":"Initiation: 04/19/2023","start_date":" 04/19/2023","primary_txt":" Primary completion: 07/16/2025","primary_completion_date":" 07/16/2025","study_txt":" Completion: 03/16/2026","study_completion_date":" 03/16/2026","last_update_posted":"2023-05-09"},{"id":"ba0b67f1-c5e5-4ec3-a0a5-2e11cd4844d5","acronym":"IUNU-RC","url":"https://clinicaltrials.gov/study/NCT05768464","created_at":"2023-03-14T14:01:50.999Z","updated_at":"2024-07-02T16:35:53.327Z","phase":"Phase 2","brief_title":"Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors","source_id_and_acronym":"NCT05768464 - IUNU-RC","lead_sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","biomarkers":" SMARCB1 • FH","pipe":"","alterations":" ","tags":["SMARCB1 • FH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • axitinib"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/30/2027","study_completion_date":" 12/30/2027","last_update_posted":"2023-03-14"},{"id":"cfec14aa-1813-413d-8c1f-46e334b4c105","acronym":"","url":"https://clinicaltrials.gov/study/NCT01385059","created_at":"2021-01-18T05:40:56.063Z","updated_at":"2024-07-02T16:35:53.943Z","phase":"Phase 2","brief_title":"Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer","source_id_and_acronym":"NCT01385059","lead_sponsor":"City of Hope Medical Center","biomarkers":" FLT1","pipe":"","alterations":" ","tags":["FLT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e axitinib"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 10/28/2011","start_date":" 10/28/2011","primary_txt":" Primary completion: 10/09/2013","primary_completion_date":" 10/09/2013","study_txt":" Completion: 10/09/2013","study_completion_date":" 10/09/2013","last_update_posted":"2023-03-07"},{"id":"d5162325-5b3c-4d42-94a5-aa1bdf6c5de5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03839498","created_at":"2021-01-18T18:57:18.296Z","updated_at":"2024-07-02T16:36:02.878Z","phase":"Phase 2","brief_title":"Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma","source_id_and_acronym":"NCT03839498","lead_sponsor":"Columbia University","biomarkers":" SDHB","pipe":" | ","alterations":" VHL mutation • SDHB mutation","tags":["SDHB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VHL mutation • SDHB mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e axitinib"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 01/22/2019","start_date":" 01/22/2019","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2022-10-07"},{"id":"b2b72699-2121-4672-a707-c79e0e387b20","acronym":"JAVELIN Renal 100","url":"https://clinicaltrials.gov/study/NCT02493751","created_at":"2022-02-18T20:54:54.135Z","updated_at":"2024-07-02T16:36:16.915Z","phase":"Phase 1b","brief_title":"A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)","source_id_and_acronym":"NCT02493751 - JAVELIN Renal 100","lead_sponsor":"Pfizer","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • axitinib"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 10/26/2015","start_date":" 10/26/2015","primary_txt":" Primary completion: 04/03/2018","primary_completion_date":" 04/03/2018","study_txt":" Completion: 03/04/2021","study_completion_date":" 03/04/2021","last_update_posted":"2022-02-18"}]